Transgene to sell 'Erythropoietin' to German firm 
Transgene Biotek, a Hyderabad-based biotechnology firm, announced that it will sell one of its bio-generic products 'Erythropoietin', to a German firm Tss Export GmbH for a total consideration of $5 million (over Rs 26 crore).
Erythropoietin is a hormone produced by the kidney that promotes the formation of red blood cells in the bone marrow.
In a regulatory filing the company said the management of Transgene has formalised the sale of technology of one of its bio-generic products, Erythropoietin to 'Tss Export GmbH FZE' for a total consideration of $5 million.
"This sale of technology is expected to be completed during a period of approximately 5-6 months," the company said.
With the market for Erythropoietin set to become very competitive, the management of Transgene has decided to monetise some of the dormant technologies through either out-licensing or strategic partnerships within and outside India, it said. The company had earlier out-licensed two of its technologies - a recombinant Hepatitis B Vaccine to one of the largest vaccine producers in the world, and more recently Orlistat to one of the biggest Indian pharma companies with a significant presence on the global arena.
